Clinical Evaluation of Sizofilan as Assistant Immunotherapy in Treatment of Head and Neck Cancer

Yo Kimura Department of Otolaryngology, Yamagata University School of Medicine, Yamagata, 990-23, Japan

Hitoshi Tojima Department of Otolaryngology, Yamagata University School of Medicine, Yamagata, 990-23, Japan

Shigeru Fukase Department of Otolaryngology, Yamagata University School of Medicine, Yamagata, 990-23, Japan

Kazuhiko Takeda Department of Otolaryngology, Yamagata University School of Medicine, Yamagata, 990-23, Japan

Abstract

Sizofilan (SPG), a simple glucan produced in a culture medium by Schizophyllum commune Feries, was used as an assistant immunotherapy in 15 patients with head and neck cancer. The cumulative 5-year survival rate was 86.7% in the SPG-treated group and 73.4% in the control group. Immunological parameters showed that the SPG group quickly recovered the cellular immunity damaged by radiation, chemotherapy and surgical procedure. SPG was found to be effective as an assistant immunotherapeutic agent in the treatment of head and neck

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Clinical Evaluation of Sizofilan as Assistant Immunotherapy in Treatment of Head and Neck Cancer

Information for

Open access

Opportunities

Help and information

Clinical Evaluation of Sizofilan as Assistant Immunotherapy in Treatment of Head and Neck Cancer

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature